After announcing it plans to spend an additional $1.67 million over the next two years, the Global Fund to Fight AIDS, Tuberculosis and Malaria Board on Friday at the end of its 26th meeting in Geneva said (.pdf) its “secretariat will present at an upcoming board meeting in September new funding models drafted in consultation with recipient countries and other stakeholders,” and the board will “announce funding decisions no later than April 2013,” Devex reports.
Al Jazeera’s “Counting the Cost” program on Saturday focused on the fight against malaria and the “business behind its treatment and prevention.” According to the program, progress against malaria “is being threatened in these tough economic times. There is a $3 billion shortfall in funding for malaria treatment and prevention.” The program reports on drug-resistant malaria strains in South-East Asia; examines a vaccine candidate under development by GlaxoSmithKline; speaks with Jo Lines of the London School of Hygiene and Tropical Medicine and Christoph Benn of the Global Fund to Fight AIDS, Tuberculosis and Malaria about the impact of the international financial crisis on the fight against the disease; and discusses a mobile phone app developed by a group of medical students that would help people receive a quicker diagnosis and treatment (Santamaria, 5/26).
Medecins Sans Frontieres (MSF), the largest provider of antiretroviral treatment (ART) in Burma, also known as Myanmar, are calling for the gap between the need for and access to ART in the country to be closed, the Guardian reports. Approximately 240,000 people live with HIV in Burma, and doctors say half are in need of “urgent” ART, but national data estimates less than 30,000 were receiving ART in 2010, the newspaper writes, adding, “In a country where nearly 33 percent of people live below the poverty line, thousands of Burmese are unlikely ever to be able to afford ART, which, according to [MSF], cost $30 a month.”
The Global Fund to Fight AIDS, Tuberculosis and Malaria “expects to have an additional $1.6 billion to fund projects in 2012-2014, [the fund’s General Manager Gabriel Jaramillo] said on Wednesday, a turnaround from a funding freeze last year,” Reuters reports (Miles, 5/9). “The new funds are a result of ‘strategic decisions made by the Board, freeing up funds that can be invested in countries where there is the most pressing demand,’ a statement by the fund said,” according to PlusNews (5/10). “The money includes funds from new donors, from traditional donors who are advancing their payments or increasing contributions and from some donors, such as China, that have offered to support projects in their own country to free up cash for more pressing needs elsewhere, Jaramillo said,” Reuters notes (5/9). “This forecast is better than expected, and it comes from the fantastic response we are getting to our transformation,” Jaramillo said, adding, “But we need more to get the job done. Countries that implement our grants are saving more and more people, but demand for services is still enormous,” according to the statement (5/9).
“This year marks the 10th anniversary of the Global Fund to Fight AIDS, Tuberculosis and Malaria, the world’s most powerful tool in the fight against the three pandemics,” Jonathan Klein, co-founder and CEO of Getty Images, Inc., writes in this post in the Huffington Post Blog, adding, “Since 2002, the Global Fund has saved and improved millions of lives.” Klein notes the Board of the Global Fund convened in Geneva, Switzerland, for its 26th meeting last week, where Board members “discussed progress to date on the current transformation of the Global Fund from emergency response to long-term sustainability.”
The board of the Global Fund to Fight AIDS, Tuberculosis and Malaria began a two-day meeting in Geneva on Thursday, “with one topic high on the agenda: a new funding model,” Devex’s “Development Newswire” reports. “The board will tackle aspects of a new funding model, which, according to Global Fund Director of Communications Seth Faison, ‘will change the way the Global Fund has made grants for 10 years,'” the news service writes, adding that the model, according to the International HIV/AIDS Alliance, “will see the Global Fund dropping its ’round’ grant-making process and replacing it with a ‘more flexible’ system.” In addition, “an ‘iterative dialogue process’ is also reportedly being explored,” Devex reports. “The proposed reforms seem good for the fund and its beneficiaries … [b]ut some have expressed their concerns on the funding model under consideration, specifically on the ‘historical disease application’ approach,” the news service writes (Ravelo, 9/13). According to an article on the Stop TB Partnership website, the new approach “would cap the proportion of funding available to tuberculosis (TB) projects at 16 percent,” and the proposal, “which is based on the proportion of grants awarded to TB in the past, met with strong objections from the community of people working on TB worldwide” (9/13).
Amanda Glassman, director of global health policy and a senior fellow at the Center for Global Development (CGD), and Kate McQueston, a program coordinator at CGD, write in the center’s “Global Health Policy” blog that a reduction in AIDS funding to Ethiopia from PEPFAR and the Global Fund to Fight AIDS, Tuberculosis and Malaria “might be warranted due to epidemiological trends and improved efficiency, or might cripple progress as health programs dependent on external donors are cut back,” but “with the current poor status of basic information on beneficiaries and costs, it’s difficult to judge whether these cuts are good or bad.” They outline the history of AIDS funding in Ethiopia, posit what future funding might encompass, and say additional information is needed from PEPFAR, the Global Fund, and the Ethiopian government in order to know the true impacts of reduced funding (9/11).
In this episode of the Center for Global Development’s (CGD) “Global Prosperity Wonkcast,” CGD’s Lawrence MacDonald interviews Amanda Glassman, a senior fellow and director of the global health policy program at the center, about global health funding in “this austere budget climate.” In an accompanying blog post, MacDonald notes “generating ‘value for money’ (VFM) is a top concern for global health funding agencies and their donors, who want the biggest bang for their buck in terms of lives saved and diseases controlled.” According to the blog, the discussion focuses on the Global Fund to Fight AIDS, Tuberculosis and Malaria, “a multilateral agency that emerged from the G8 meeting process in 2002 when times were better and global health was seen as an area where money could make a difference” (9/5).
The Affordable Medicines Facility-malaria (AMFm) — an innovative financing mechanism that subsidizes the cost of artemisinin-based combination therapies (ACTs) in order to expand access to the most effective treatment for malaria — “brought more than 100 million doses of malaria drugs to clinics and pharmacies in 2011” and “also increased access to the top malaria medicines by 26 to 52 percent in six countries,” according to results from the first phase of the program, which is hosted and managed by the Global Fund to Fight AIDS, Tuberculosis and Malaria, NPR’s “Shots” blog reports. The results of the evaluation, released on Wednesday in Washington, D.C., do not estimate how many lives were saved because of improved access to effective malaria medications, as “AMFm ran for only a year and half in most countries,” according to the blog. “The AMFm negotiated with drugmakers to reduce ACTs prices, and then the Global Fund subsidized the initial purchasing of the drugs by clinics and pharmacies,” the blog notes.
The Global Fund to Fight AIDS, Tuberculosis and Malaria has published Issue 8 of its newsletter, the “Global Fund News Flash.” The issue reports on the Board’s approval of a new funding approach; says “the Board extended the mandate of the Global Fund to host the Affordable Medicines Facility-malaria for another year after the end of its pilot phase in December”; notes the Global Fund adopted a code of conduct for grant recipients; and profiles Linda Mafu, head of civil society and political advocacy at the Global Fund (9/20).